Evidence Library

Filter by drug, type, year, and open access.

Drug

Type

Year ≥

Sort

Open access

Showing 151–200 of 427 results

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)• Drug: semaglutide-wegovyDOI
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine (2021)• Drug: tirzepatide-mounjaroDOI
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine (2021)• Drug: tirzepatide-zepboundDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: clonazepamDOI
Efficacy of Quetiapine in Bipolar Depression: Meta‑analysis — Meta‑analysis (2020)• Drug: quetiapine
Comparative effects of 18 antipsychotics on metabolic function in schizophrenia: systematic review and network meta-analysis. — The Lancet Psychiatry (2020)• Drug: olanzapineOpen accessDOI PMID PMCID
Lurasidone in bipolar depression: meta‑analysis — Meta‑analysis (2020)• Drug: lurasidone
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial — JAMA Psychiatry (2020)• Drug: lumateperoneDOI PMID
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: alprazolamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: alprazolamOpen access
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: diazepamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: diazepamOpen access
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: clorazepateDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: clorazepateDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: clorazepateOpen access
The effects of prazosin on sleep disturbances in post-traumatic stress disorder: systematic review and meta-analysis — Sleep Medicine (2020)• Drug: prazosinOpen accessDOI PMID PMCID
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: estazolamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: estazolamOpen access
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: flurazepamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: flurazepamOpen access
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: quazepamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: quazepamOpen access
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: temazepamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: temazepamOpen access
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: triazolamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: triazolamOpen access
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: oxazepamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: oxazepamDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: oxazepamOpen access
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: chlordiazepoxideDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: chlordiazepoxideDOI
FDA boxed warning update for benzodiazepines (abuse, addiction, dependence, withdrawal) — FDA Drug Safety Communication (2020)• Drug: chlordiazepoxideOpen access
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy — Sleep (2020)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: buprenorphineDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: buprenorphine-naloxoneDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: methadoneDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: naltrexone-extended-releaseDOI PMID
Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials — Journal of Drug Assessment (2020)• Drug: lofexidineOpen accessDOI PMID PMCID
Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis — BMJ (2020)• Drug: acamprosateOpen accessDOI PMID PMCID
Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis — BMJ (2020)• Drug: disulfiramOpen accessDOI PMID PMCID
ASAM guideline on benzodiazepines — Journal of Addiction Medicine (2020)• Drug: lorazepamDOI
Effect of olanzapine/samidorphan combination on weight gain — American Journal of Psychiatry (2020)• Drug: olanzapine-samidorphanDOI
Bipolar disorder: assessment and management (NICE guideline CG185) — National Institute for Health and Care Excellence (2020)• Drug: valproate-divalproexOpen access
Quetiapine in schizophrenia and bipolar disorder: systematic review — Systematic review (2019)• Drug: quetiapine
Risperidone and prolactin: safety review — Review (2019)• Drug: risperidone
Metabolic effects of olanzapine: systematic review — Systematic review (2019)• Drug: olanzapine
Valproate for acute mania — Cochrane Database of Systematic Reviews (2019)• Drug: valproateDOI
Iloperidone for schizophrenia: updated systematic review and meta-analysis — International Journal of Neuropsychopharmacology (2019)• Drug: iloperidoneDOI PMID
FDA boxed warning for serious injuries caused by complex sleep behaviors with certain prescription insomnia medicines — FDA Drug Safety Communication (2019)• Drug: eszopicloneOpen access
FDA boxed warning for serious injuries caused by complex sleep behaviors with certain prescription insomnia medicines — FDA Drug Safety Communication (2019)• Drug: zolpidemOpen access